Principal Financial Group Inc. Has $584,000 Stake in Ultragenyx Pharmaceutical Inc (RARE)

Principal Financial Group Inc. cut its stake in shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) by 19.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 13,440 shares of the biopharmaceutical company’s stock after selling 3,214 shares during the quarter. Principal Financial Group Inc.’s holdings in Ultragenyx Pharmaceutical were worth $584,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the company. BlackRock Inc. grew its position in shares of Ultragenyx Pharmaceutical by 2.8% during the fourth quarter. BlackRock Inc. now owns 4,476,812 shares of the biopharmaceutical company’s stock worth $194,652,000 after buying an additional 123,409 shares in the last quarter. Federated Investors Inc. PA lifted its stake in Ultragenyx Pharmaceutical by 4.7% during the third quarter. Federated Investors Inc. PA now owns 1,484,271 shares of the biopharmaceutical company’s stock worth $113,309,000 after purchasing an additional 66,720 shares during the last quarter. First Trust Advisors LP lifted its stake in Ultragenyx Pharmaceutical by 16.5% during the fourth quarter. First Trust Advisors LP now owns 1,471,934 shares of the biopharmaceutical company’s stock worth $64,000,000 after purchasing an additional 208,468 shares during the last quarter. Clearbridge Investments LLC lifted its stake in Ultragenyx Pharmaceutical by 5.6% during the third quarter. Clearbridge Investments LLC now owns 1,009,872 shares of the biopharmaceutical company’s stock worth $77,094,000 after purchasing an additional 53,460 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in Ultragenyx Pharmaceutical by 2.0% during the fourth quarter. Northern Trust Corp now owns 580,580 shares of the biopharmaceutical company’s stock worth $25,243,000 after purchasing an additional 11,258 shares during the last quarter. 98.62% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ RARE opened at $64.43 on Monday. Ultragenyx Pharmaceutical Inc has a twelve month low of $37.44 and a twelve month high of $90.98. The company has a market capitalization of $3.30 billion, a price-to-earnings ratio of -8.72 and a beta of 2.22.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, February 19th. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.74) by $0.01. Ultragenyx Pharmaceutical had a negative return on equity of 35.26% and a negative net margin of 383.75%. The company had revenue of $16.26 million during the quarter, compared to analysts’ expectations of $13.30 million. As a group, equities research analysts expect that Ultragenyx Pharmaceutical Inc will post -6.65 EPS for the current year.

In other Ultragenyx Pharmaceutical news, CFO Shalini Sharp sold 14,800 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $70.00, for a total value of $1,036,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 8.40% of the stock is currently owned by insiders.

RARE has been the subject of several recent analyst reports. Morgan Stanley upgraded Ultragenyx Pharmaceutical from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $68.00 to $83.00 in a research note on Wednesday, March 27th. BidaskClub upgraded Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 9th. Cowen restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 7th. Raymond James cut Ultragenyx Pharmaceutical from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 2nd. Finally, SunTrust Banks boosted their target price on Ultragenyx Pharmaceutical to $71.00 and gave the stock a “buy” rating in a research note on Wednesday, January 23rd. Six equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $76.83.

COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/04/22/principal-financial-group-inc-has-584000-stake-in-ultragenyx-pharmaceutical-inc-rare.html.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Recommended Story: What does the Dow Jones Industrial Average (DJIA) measure?

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.